跳至主要内容
临床试验/NCT01030458
NCT01030458已完成4 期

Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial

KU Leuven7 个研究点 分布在 5 个国家目标入组 183 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
KU Leuven
入组人数
183
试验地点
7
主要终点
Sitting Systolic Blood Pressure on Automated Measurement

研究概览

简要总结

The purpose of this study is to compare the blood pressure lowering efficacy of a treatment regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II type-1 receptor blocker with the recommended treatment regimen based on a low-dose thiazide diuretic combined with a beta-blocker.

详细描述

Primary objective:

Sitting systolic blood pressure (average of three readings) will be the primary outcome variable.

Secondary

  1. To compare the time interval between the two treatment groups, which after randomisation will be required, to reach and maintain the target defined as a blood pressure below 140 mm Hg systolic and 90 mm Hg diastolic;
  2. To compare the duration of follow-up, during which a steady blood pressure control will be achieved;
  3. To evaluate the incidence of adverse events, symptoms, biochemical abnormalities and ECG changes in the two treatment groups;
  4. To assess the adherence to antihypertensive treatment as well as the rate of drop-outs in both treatment arms during a six-month period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 69 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Women or men within an age range from 30 to 69 years with uncomplicated hypertension.
  • Blood pressure measured in the sitting position after at least 5 minutes rest (average of three readings at the last run-in-visit) should range from 140 to 179 mm Hg systolic or from 90 to 109 mm Hg diastolic (grades 1 or 2 of hypertension). Patients must have uncomplicated hypertension with a maximum of two additional risk factors, as defined in the 2007 guidelines of the European Societies of Hypertension and Cardiology.
  • Systolic blood pressure in the upright position must be at least 110 mm Hg (mean of three readings obtained immediately after the patient has assumed a standing position).
  • Patients who have never been treated for hypertension or in whom previous antihypertensive drug treatment has been discontinued for at least four weeks before the last run-in visit can be randomised. If two weeks after discontinuation of previous antihypertensive treatment the blood pressure is higher than 160 mm Hg systolic or higher than 100 mm Hg diastolic and if the patient has complaints, the patient can be randomised immediately to active blood pressure lowering treatment with either the newer or older antihypertensive drugs.
  • The patient must provide informed written consent.

排除标准

  • Premenopausal women not applying anticonception.
  • A history of cardiovascular disease.
  • Secondary hypertension.
  • Electrocardiographic left ventricular hypertrophy.
  • More than two cardiovascular risk factors in addition to hypertension.
  • Diabetes mellitus.
  • Renal dysfunction.
  • Recent treatment with two or more antihypertensive drugs or a contra-indication to discontinue blood pressure lowering agents for 4 weeks.
  • Severe non-cardiovascular disease.
  • Known contra indications for the first-line study medications.

研究组 & 干预措施

amlodipine plus valsartan

Experimental

In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.

干预措施: amlodipine 5/10 mg per day plus valsartan 160 mg/day (Drug)

hydrochlorothiazide plus bisoprolol

Active Comparator

In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol

干预措施: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day (Drug)

结局指标

主要结局

Sitting Systolic Blood Pressure on Automated Measurement

时间窗: 6 months follow-up after randomization

Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome.

次要结局

  • Side-effects to Study Medications(6 months follow-up after randomization)
  • Time to Blood Pressure Control(6 months follow-up after randomization)
  • Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up(6 months follow-up after randomization)

研究者

发起方
KU Leuven
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jan A. Staessen

Professor of Medicine, MD, PhD

KU Leuven

研究点 (7)

Loading locations...

相似试验